Eyevensys

Eyevensys created in 2009 is headquartered in Paris, France. It develops and will commercialize patented, minimally invasive, targeted,

Eyevensys created in 2009 is headquartered in Paris, France. It develops and will commercialize patented, minimally invasive, targeted, non-viral gene therapy-based solutions for the sustainable intraocular production of any secreted therapeutic protein or peptide. EYEVENSYS’s technology consists of a patented device that allows the calibrated injection in the ciliary muscle of a plasmid containing the gene encoding for a therapeutic peptide or protein. The sustainability of the gene expression is induced thanks to a patented proprietary electrotransfer technology or corticostranfection technology. The ciliary muscle is used for the transfection of therapeutic genes, playing then the role of a “factory” for the intraocular production of gene therapies, that will spread to the overall eye sphere, particularly into the vitreous cavity.